Prices delayed by at least 15 minutes | Print
Shield Therapeutics PLC (STX)
ORD 1.5POpen
2.35p
Previous close
2.26p
Trade high
2.50p
Volume
2,704,359
Year high
5.87p
Year low
1.2025p
Dividend yield
–
Market capitalisation
£24.48 mn
P/E ratio
32.15
ISIN
GB00BYV81293
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPPand can be used with Dividend reinvestment
Share price
Company profile
Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group's main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment.
News
Recent trades
| Date | Time | Price | Quantity | Value (£) |
|---|---|---|---|---|
| 25/04/2025 | 04:08:38 | 2.389 | 50,000 | 1,194.50 |
| 25/04/2025 | 04:08:17 | 2.389 | 41,649 | 994.99 |
| 25/04/2025 | 04:07:56 | 2.338 | 55 | 1.29 |
| 25/04/2025 | 03:53:00 | 2.47 | 100,000 | 2,470.00 |
| 25/04/2025 | 03:53:00 | 2.47 | 100,000 | 2,470.00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.